INVENTIVA SA (IVA)

NASDAQHealth CareBiotechnologySnapshot 2026-11-04

$3.63-6.20%

Close 2026-11-05 · 1-day change

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge INVENTIVA SA’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Nov 3, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	No revenue guidance available	1.1M
EPS	No EPS guidance available	-0.791
Annual ending 2026-12-31
Revenue	No revenue guidance available	3.4M
EPS	No EPS guidance available	-0.618
Annual ending 2027-12-31
Revenue	No revenue guidance available	11.07M
EPS	No EPS guidance available	-0.612

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manageable cash burn	A supporting condition in INVENTIVA SA's published investment case. The stated target is EPS of -$0.74.	Intact	EPS worsens to below -$1.00	Diluted EPS: EUR -0.26 per share FY2026-Q2; GAAP. Published target: EPS of -$0.74. Annual target cannot be compared with a quarterly or TTM observation. Sep 28, 2026-0.26 EUR/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Lanifibranor pivotal trial success	A primary condition in INVENTIVA SA's published investment case. The stated target is Positive pivotal readout.	Under Pressure	Trial fails to meet primary endpoint	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth to $2.2M	A primary condition in INVENTIVA SA's published investment case. The stated target is >= $2.2M revenue.	Intact	Revenue falls below $1.5M in FY27	Revenue: EUR 1.305M FY2026-Q2; GAAP. Published target: >= $2.2M revenue. Annual target cannot be compared with a quarterly or TTM observation. Sep 28, 20261,305,000 EUR · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Nov 3, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.61

$-0.61 → $-0.61 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-11-02	$-0.61	$11,065,240	5 / 7
2026-11-03	$-0.61	$11,065,240	5 / 7
2026-11-04	$-0.61	$11,065,240	5 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	13	0	0
2026-07-01	14	0	0
2026-08-01	14	0	0
2026-09-01	14	0	0
2026-10-01	13	0	0
2026-11-01	12	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Oct 6–Nov 4 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manageable cash burnDiluted EPS: EUR -0.26 per share
Lanifibranor pivotal trial successPublished status: Under Pressure
Revenue growth to $2.2MRevenue: EUR 1.305M

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-59.9%Maximum drawdown · trailing year

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.